Evidence map›Paper›PMID 38293297›Full record

ArticleFrontiers in medicine2023

Comprehensive next-generation sequencing reveals low-grade fibromyxoid sarcoma of the vulva missed by morphological diagnosis: a case report.

Shuang Tan, Hongruo Liu, Evenki Pan, Siye Liu, Jiangyan Zhang, Jie Wang, Ning Wang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shuang Tan *Department of Gynecology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Hongruo Liu *Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Evenki PanDepartment of Medical, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Siye LiuDepartment of Medical, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Jiangyan ZhangDepartment of Medical, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Jie WangDepartment of Pathology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Ning WangDepartment of Gynecology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft tissue tumor composed of bland spindled cells in a variably fibrous to myxoid stroma. Its occurrence in the vulva region is rare, and thus, it may not be always taken into account in the differential diagnosis. Here, we describe a 34-year-old woman presented with a right vulvar mass and underwent complete surgical excision. The final pathologic diagnosis revealed LGFMS of the vulva based on the morphological, immunophenotypic, and molecular genetic features. The patient has not experienced a local or metastatic recurrence after 9-month follow-up. Despite being rare, LGFMS of the vulva should be considered when making a diagnosis of vulvar lesions. We also report that the genetic testing by next-generation sequencing (NGS) represents a very useful tool for the differential diagnosis of LGFMS from its mimics. Moreover, we have reviewed the literature on LGFMS of the vulva and summarized the characteristics of the patients, providing assistance for the diagnosis of such patients. Most vulvovaginal LGFMS can be fully removed through surgery. However, ongoing monitoring over the long term is essential as local and/or distant spread can occur decades after the initial diagnosis.

Indexed as

FUS-CREB3L2 fusionlow-grade fibromyxoid sarcomaMUC4 proteinnext-generation sequencingvulva

Identifiers

PMID38293297
PMCPMC10824949
OpenAlexW4390917222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.